CPRC
ALNY icon

Consolidated Portfolio Review Corp’s Alnylam Pharmaceuticals ALNY Stock Holding History

Consolidated Portfolio Review Corp’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-601
Closed -$274K – 47
2025
Q3 		$274K Buy
+601
New +$245K 0.03% 391

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Consolidated Portfolio Review Corp's ALNY Position: Q4 2025 in Review

Consolidated Portfolio Review Corp sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 601 shares — an estimated $274K sold.

Consolidated Portfolio Review Corp first reported a position in ALNY in Q3 2025 and held it in 1 quarter. The position peaked at $274K in Q3 2025. 850 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

  • Consolidated Portfolio Review Corp reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Consolidated Portfolio Review Corp sold 601 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $274K.
  • Consolidated Portfolio Review Corp first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Consolidated Portfolio Review Corp's Alnylam Pharmaceuticals position peaked at $274K in Q3 2025.
  • 850 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Consolidated Portfolio Review Corp's 13F filing for Q4 2025, filed 26 Jan 2026.